Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785408 · ClinicalTrials.gov registry record · Phase 2
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT00785408 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 273 participants.
The verdict
NCT00785408, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
Interventions
- DRUG placebo
- DRUG AC2307
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785408
The ClinicalTrials.gov registry entry for NCT00785408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00785408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785408 about?
NCT00785408 is a clinical study titled "Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects". A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.
What is the current status of trial NCT00785408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2008-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00785408?
The interventions under investigation include: placebo (DRUG), AC2307 (DRUG).
Who is sponsoring clinical trial NCT00785408?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.